|
|
Article: Preclinical Anticancer Firm TetraLogic Brings In $36M.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
TetraLogic Pharmaceuticals Corp. raised $36 million in a Series B round of financing to move its lead oncology program closer to the clinic.
"With these drugs," President and CEO John Gill told BioWorld Today, "we'll be able to remove a fundamental block at the end of the apoptosis pathway that cancer cells use to survive."
The Malvern, Pa.-based company's research is based on decreasing excess levels of a protein called XIAP, which gets up-regulated by cancer cells, through a new class of small molecules that mimic Smac, the second mitochondria-derived activator of caspase.
The drugs are being developed to overcome ...